NDA 022522 · Astrazeneca
Daliresp
Roflumilast · Oral · Phosphodiesterase 4 Inhibitor
NovelLast checked: Nov 20, 2026Latest source record: Jan 23, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Feb 28, 2011
Approved uses
3
Original approval plus efficacy supplements
Registered trials
129
45 Phase 3, 14 recruiting
FAERS reports
6,156
4,118 serious, 958 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 12, 2020.
DALIRESP ® is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. DALIRESP is a selective phosphodiesterase 4 inhibitor indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. ( 1 , 14 ) Limitations of Use : • DALIRESP is not a bronchodilator and is not indicated for the relief of acute bronchospasm. ( 1, 14 ) • DALIRESP 250 mcg is a starting dose, for the first 4 weeks of treatment only and is not the effective (therapeutic) dose. ( 2, 14 ) Limitations of Use DALIRESP is not a bronchodilator and is not indicated for the relief of acute bronchospasm. DALIRESP 250 mcg is a starting dose, for the first 4 weeks of treatment only and is not the effective (therapeutic) dose.
Mechanism: Roflumilast and its active metabolite (roflumilast N-oxide) are selective inhibitors of phosphodiesterase 4 (PDE4). Roflumilast and roflumilast N-oxide inhibition of PDE4 (a major cyclic-3′,5′-adenosine monophosphate (cyclic AMP)-metabolizing enzyme in lung tissue) activity leads to accumulation of intracellular cyclic AMP. While the specific mechanism(s) by which DALIRESP exerts its therapeutic action in COPD patients is not well defined, it is thought to be related to the effects of increased intracellular cyclic AMP in lung cells.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 23, 2018 Supplement 9 · Efficacy LabelMedication GuideLetter
- Aug 31, 2017 Supplement 8 · Efficacy LabelLetter
- Feb 28, 2011 Original approval · Type 1 - New Molecular Entity NovelLabelReviewSummary Review
2 products under this application
- DALIRESP · ROFLUMILAST 500MCG · TABLET, ORAL · Prescription · TE AB
- DALIRESP · ROFLUMILAST 250MCG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Roflumilast" as an intervention, any sponsor and status, largest first.
Chiesi Farmaceutici S.p.A.Industry
NCT04636814 · 3,973 participants · Start Jul 12, 2021 · Primary completion Dec 23, 2025
Drug: CHF6001 1600µg; CHF6001 3200µg and 2 more · For: Chronic Obstructive Pulmonary Disease
Sites: Andalusia, Alabama; Foley, Alabama; Guntersville, Alabama · 460 sites in all
- Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01443845 · 2,354 participants · Start Sep 30, 2011 · Primary completion Nov 30, 2015
Drug: Roflumilast; Placebo · For: COPD; COPD Exacerbation; Lung Diseases and 4 more
Sites: Anniston, Alabama; Athens, Alabama; Florence, Alabama · 338 sites in all
- Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00163527 · 2,054 participants · Start Apr 2003 · Primary completion Nov 2005
Drug: Roflumilast · For: Asthma
Sites: Cities in Georgia, Georgia; Cities in Austria, Austria; Cities in Croatia, Croatia · 24 sites in all
- Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01329029 · 1,945 participants · Start May 2011 · Primary completion Mar 2014
Drug: Roflumilast; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Box Hill, Australia; Clayton, Australia; Concord, Australia · 180 sites in all
- Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00297115 · 1,568 participants · Start Mar 2006 · Primary completion Apr 2008
Drug: Roflumilast; Placebo · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Bayou La Batre, Alabama; Birmingham, Alabama; Huntsville, Alabama · 287 sites in all
- Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00297102 · 1,523 participants · Start Feb 2006 · Primary completion Jul 2008
Drug: Roflumilast; Placebo · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Fullerton, California; Los Angeles, California; Palmdale, California · 179 sites in all
- Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPDPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02165826 · 1,323 participants · Start May 1, 2014 · Primary completion Sep 1, 2015
Drug: Roflumilast; Roflumilast Placebo and 1 more · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Bardejov, Slovakia; Spišská Nová Ves, Slovakia
- Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic DermatitisPivotal-lookingCompleted
Arcutis Biotherapeutics, Inc.Industry
NCT04804605 · 1,220 participants · Start Feb 25, 2021 · Primary completion May 28, 2024
Drug: ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% · For: Atopic Dermatitis Eczema
Sites: Birmingham, Alabama; Scottsdale, Arizona; Bryant, Arkansas · 92 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea1,062
- death743
- chronic obstructive pulmonary disease669
- diarrhoea539
- pneumonia470
- nausea461
- weight decreased443
- cough366
- headache359
- drug ineffective322
- off label use317
- dizziness300
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 5 |
| 2011 | 77 |
| 2012 | 676 |
| 2013 | 493 |
| 2014 | 460 |
| 2015 | 396 |
| 2016 | 427 |
| 2017 | 325 |
| 2018 | 329 |
| 2019 | 389 |
| 2020 | 360 |
| 2021 | 336 |
| 2022 | 341 |
| 2023 | 448 |
| 2024 | 341 |
| 2025 | 391 |
| 2026 | 362 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Daliresp (Roflumilast)
2024 spending
$4.8M
Beneficiaries
3,123
9,113 claims
Per beneficiary
$1,539
$13.55 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $189,731,323 |
| 2021 | $199,140,335 |
| 2022 | $181,447,200 |
| 2023 | $28,569,435 |
| 2024 | $4,805,759 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu DK, Chu AWL, Rayner DG, et al. · J Allergy Clin Immunol 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Topical anti-inflammatory treatments for eczema: network meta-analysis.
Lax SJ, Van Vogt E, Candy B, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Focused update: Guidelines of care for the management of atopic dermatitis in adults.
Davis DMR, Frazer-Green L, Alikhan A, et al. · J Am Acad Dermatol 2025 · Systematic Review, Practice Guideline
- Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials.
Simpson EL, Eichenfield LF, Alonso-Llamazares J, et al. · JAMA Dermatol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- 2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients With Stable COPD.
Bourbeau J, Bhutani M, Hernandez P, et al. · Chest 2023 · Meta-Analysis, Systematic Review
- Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.
Blauvelt A, Draelos ZD, Stein Gold L, et al. · J Am Acad Dermatol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.